Preliminary clinical trial of AR-101 anti-P. aeruginosa(Pa) IgM mAb in pneumonia patients provides important proof-of-concept evidence that anti-Pa mAbs can be safe and effective as adjunctive therapies to antibiotics. This important milestone provides the impetus to refine and improve on this t...

TechnologyOverview MabIgXTechnology StabilizationofBiopharma HomeAboutProductsTechnologiesPartnershipNewsContact Aridis Pharmaceuticals 2009-2013 Le3 Web Designs Search Site Map | Privacy Policy | Financial Conflict of Interest Policy Technologies Overview Our unrivaled portfolio of anti-infe...

HomeAboutProductsTechnologiesPartnershipNewsContact Aridis Pharmaceuticals 2009-2013 Le3 Web Designs Search Site Map | Privacy Policy | Financial Conflict of Interest Policy Site Map Home About About Aridis Executive Team Scientific Advisory Board Clinical Advisory Board Produ...

TechnologyOverview MabIgXTechnology StabilizationofBiopharma HomeAboutProductsTechnologiesPartnershipNewsContact Aridis Pharmaceuticals 2009-2013 Le3 Web Designs Search Site Map | Privacy Policy | Financial Conflict of Interest Policy Conventional pharmaceutical protein stabilization approach...

Panaecin has broad bactericidal activity against Gram negative and Gram positive bacteria, including antibiotic resistant strains and highly resistant biofilms. The core activity of Panaecin is gallium, which functions as a potent iron analog and inhibits critical iron dependent enzymatic pathwa...